Literature DB >> 11499806

Comparative analysis of IFN-gamma B7.1 and antisense TGF-beta gene transfer on the tumorigenicity of a poorly immunogenic metastatic mammary carcinoma.

R S Wu1, J J Kobie, D G Besselsen, T C Fong, V D Mack, J A McEarchern, E T Akporiaye.   

Abstract

Cancer progression is attributed in part to immune evasion strategies that include lack of co-stimulation, down-regulation of cell surface MHC molecules, and secretion of immunosuppressive factors, such as transforming growth factor-beta (TGF-beta). Gene therapy has been employed to counter these mechanisms of immune evasion by transference of B7.1, IFN-gamma or antisense TGF-beta genes into tumor cells, resulting in cell surface expression of B7.1, upregulation of MHC class I and class II molecules, or elimination of tumor-derived TGF-beta, respectively. Although each of these transgenes has been shown to alter tumorigenicity in murine models, a direct comparison of their efficacy has not been performed. In this study, we have employed a very aggressive, poorly immunogenic and highly metastatic mammary model, 4T1, to compare the efficacy of B7.1, IFN-gamma and antisense TGF-beta gene transfer in stimulating an anti-tumor response. We demonstrate that both IFN-gamma and antisense TGF-beta gene expression significantly reduced the tumorigenicity of these cells compared to mock transduced cells, with IFN-gamma having a greater effect. In contrast, B7.1 gene transfer did not affect the tumorigenicity of 4T1 cells. The anti-tumor response directed against antisense TGF-beta-expressing 4T1 tumors was mediated by CD4+ and CD8+ T cells. However, CD8+ T cells, and not CD4+ T cells, appeared to mediate the anti-tumor response against IFN-gamma-expressing tumors. Treatment of tumor-bearing animals with IFN-gamma or antisense TGF-beta gene-modified tumor cell vaccines reduced the number of clonogenic metastases to the lungs and liver compared to treatment with mock-transduced cells. Finally, in a residual disease model in which the primary tumor was excised and mice were vaccinated with irradiated tumor cells, treatment of mice with vaccinations consisting of 4T1 cells expressing both antisense TGF-beta and IFN-gamma genes was the most effective in prolonging survival.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11499806     DOI: 10.1007/s002620100197

Source DB:  PubMed          Journal:  Cancer Immunol Immunother        ISSN: 0340-7004            Impact factor:   6.968


  8 in total

Review 1.  Lung cancer immunotherapy.

Authors:  Luis E Raez; Steven Fein; Eckhard R Podack
Journal:  Clin Med Res       Date:  2005-11

2.  Central role of IFNgamma-indoleamine 2,3-dioxygenase axis in regulation of interleukin-12-mediated antitumor immunity.

Authors:  Tao Gu; Rachael B Rowswell-Turner; Mehmet O Kilinc; Nejat K Egilmez
Journal:  Cancer Res       Date:  2009-12-22       Impact factor: 12.701

Review 3.  Regulation of interleukin-12 gene expression and its anti-tumor activities by prostaglandin E2 derived from mammary carcinomas.

Authors:  Maki Mitsuhashi; Jianguo Liu; Shanjin Cao; Xiaoyan Shi; Xiaojing Ma
Journal:  J Leukoc Biol       Date:  2004-05-03       Impact factor: 4.962

4.  Down-regulation of CD55 and CD46 expression by anti-sense phosphorothioate oligonucleotides (S-ODNs) sensitizes tumour cells to complement attack.

Authors:  S Zell; N Geis; R Rutz; S Schultz; T Giese; M Kirschfink
Journal:  Clin Exp Immunol       Date:  2007-09-28       Impact factor: 4.330

5.  Blockade of TGF-β signaling to enhance the antitumor response is accompanied by dysregulation of the functional activity of CD4+CD25+Foxp3+ and CD4+CD25-Foxp3+ T cells.

Authors:  Magdalena J Polanczyk; Edwin Walker; Daniel Haley; Bella S Guerrouahen; Emmanuel T Akporiaye
Journal:  J Transl Med       Date:  2019-07-09       Impact factor: 5.531

6.  Tocotrienols are good adjuvants for developing cancer vaccines.

Authors:  Sitti Rahma Abdul Hafid; Ammu Kutty Radhakrishnan; Kalanithi Nesaretnam
Journal:  BMC Cancer       Date:  2010-01-06       Impact factor: 4.430

7.  Tocotrienol-adjuvanted dendritic cells inhibit tumor growth and metastasis: a murine model of breast cancer.

Authors:  Sitti Rahma Abdul Hafid; Srikumar Chakravarthi; Kalanithi Nesaretnam; Ammu Kutty Radhakrishnan
Journal:  PLoS One       Date:  2013-09-19       Impact factor: 3.240

Review 8.  Nanopulse Stimulation (NPS) Induces Tumor Ablation and Immunity in Orthotopic 4T1 Mouse Breast Cancer: A Review.

Authors:  Stephen J Beebe; Brittany P Lassiter; Siqi Guo
Journal:  Cancers (Basel)       Date:  2018-03-30       Impact factor: 6.639

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.